国新健康(000503) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥37,951,381.37, representing a 38.43% increase compared to ¥27,415,350.34 in the same period last year[4] - The net profit attributable to shareholders was -¥49,423,957.16, an improvement of 12.15% from -¥56,262,309.65 year-on-year[4] - The company reported a net loss of ¥48,421,498.88 for the current period, compared to a profit of ¥1,002,458.28 in the previous period[24] - Total comprehensive income for the period was -49,442,066.65, compared to -53,418,803.17 in the same period last year, indicating a reduction in losses[31] - The net profit for the first quarter was -49,422,023.57, compared to -56,375,139.39 in the previous year, showing an improvement of approximately 12.4%[30] - The total operating profit was -49,428,527.65, an improvement from -56,366,627.23 year-over-year, reflecting a positive trend in operational performance[30] Cash Flow and Liquidity - The net cash flow from operating activities was -¥101,791,799.62, a decline of 20.98% compared to -¥84,141,757.17 in the previous year[4] - Cash inflow from operating activities totaled 23,618,915.13, up from 12,570,829.37 in the previous year, reflecting a significant increase of approximately 88%[32] - Cash outflow for operating activities was 125,410,714.75, compared to 96,712,586.54 in the previous year, representing an increase of about 30%[35] - The cash and cash equivalents at the end of the period were 238,032,127.40, down from 402,764,350.63 at the end of the previous year[38] - The cash and cash equivalents decreased by 30.93% to ¥243,721,065.22, primarily due to net cash outflows from operating activities[7] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,106,807,386.22, down 7.17% from ¥1,192,309,580.42 at the end of the previous year[4] - Total liabilities decreased to ¥369,022,827.67 from ¥405,082,955.22, showing a reduction of approximately 8.9%[21] - The total equity attributable to shareholders decreased to ¥736,169,339.00 from ¥785,613,339.24, a decline of about 6.3%[24] - The balance of contract assets rose by 112.33% to ¥49,317,794.15, driven by increased revenue during the reporting period[7] - Contract liabilities increased to ¥63,394,395.13 from ¥59,549,813.53, reflecting a growth of approximately 3.1%[21] Research and Development - The company increased its research and development expenses to ¥2,042,652.21, a significant rise of 195.89% from ¥690,346.50 in the same period last year, indicating a focus on new product and technology development[7] - The company reported a 62.09% increase in development expenditures, totaling ¥26,119,001.73, reflecting enhanced investment in new products and technologies[7] Shareholder Information - The total number of common shareholders at the end of the reporting period is 64,708[10] - The largest shareholder, China Oceanwide Holdings Group Co., Ltd., holds 25.98% of shares, totaling 235,702,593 shares[10] - The company has not disclosed any related party relationships among the top ten shareholders[10] - The company has not reported any changes in the status of shares held by major shareholders[10] Other Notable Information - The company held its first extraordinary general meeting of 2022 on March 29, 2022, to elect the new board of directors and supervisory board[14] - The company has not indicated any plans for market expansion or new product development in the current report[10] - The company recorded a total of ¥422,225.26 in non-recurring gains and losses, mainly from project investment income and government subsidies[6] - The company incurred a credit impairment loss of -2,763,987.71, compared to -12,143,044.44 in the previous year, indicating a significant reduction in credit losses[30] - The weighted average return on net assets was -6.50%, slightly down from -6.03% in the previous year[4]